BioCentury
ARTICLE | Clinical News

STI-002: Phase III data

January 25, 2016 8:00 AM UTC

A Chinese Phase III trial in 330 RA patients showed that 3 mg/kg STI-002 plus methotrexate led to an ACR20 response rate of 77%. ACR50 and ACR70 response rates were 50% and 20%, respectively. Additio...